GPC3 and hepatocellular carcinoma: A new immunotoxin based on shortened DT389 fused to humanized scFv YP7 selective to an oncophetal marker Glypican-3 (GPC3) has recently been developed and studied against hepatocellular carcinoma (HCC) cells [55].